Clarkson PLC has increased its full-year profit before tax forecast to at least £135 million for 2026 following robust trading in August and September. The company benefited from volatile but record-high freight rates and higher asset prices amid geopolitical complexities. Its Broking and Financial divisions both outperformed expectations, with a strong forward order book and completed transactions boosting results. Clarkson remains well-positioned to capitalize on market opportunities with its broad shipping platform and ongoing investments in specialist teams and technology.
Clarkson PLC's updated profit outlook follows strong shipping market conditions. For readers following Industrials-sector US stocks, here is Pluang's market snapshot as of Oct 06, 2026 09:41 WIB: Among 93 priced stocks, 44 rose and 47 fell. Notable movers include FLUX at USD 0.48 with a 1-day change of -24.22% and Pluang order activity of 36% Sell / 64% Buy, PAGS at USD 10.94 up 21.29% with 39% Sell / 61% Buy, and CHRW at USD 141.40 down 10.35% with 9% Sell / 91% Buy. Typical hold times range from 19 to 28 days.
Ethereum (ETH) maintained stability above $2,700, marking its first weekly close above this level in nine months, signaling renewed bullish sentiment. Treasury firm BitMine expanded its Ethereum holdings by 15,112 ETH, now controlling about 4.9% of t...
Bitcoin options markets have shifted toward a bullish stance, with one-week 25-delta call options now more in demand than puts, indicating traders expect price gains. This shift, first seen in August 2026, shows calls making up about 61.4% of open in...
Binance experienced a net outflow of approximately 40,000 Bitcoin over a 15-day period, reducing its reserves from 704,800 BTC to 663,100 BTC. The weekly net outflow hit 23,100 BTC, the highest since June 2023, with a daily peak of 14,300 BTC on Octo...
Nebius Group N.V. is rated a buy due to its strategic partnership with Palantir, which positions Nebius as the preferred sovereign infrastructure provider for Palantir's enterprise AI solutions targeting regulated industries. This collaboration allow...
Poolbeg Pharma has obtained a South Korean patent for POLB 001, a treatment designed to prevent cytokine release syndrome (CRS), a serious side effect of cancer immunotherapy. The patent covers the use of p38 MAP kinase inhibitors to prevent CRS and ...
